JP2013542930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542930A5 JP2013542930A5 JP2013531721A JP2013531721A JP2013542930A5 JP 2013542930 A5 JP2013542930 A5 JP 2013542930A5 JP 2013531721 A JP2013531721 A JP 2013531721A JP 2013531721 A JP2013531721 A JP 2013531721A JP 2013542930 A5 JP2013542930 A5 JP 2013542930A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- topical pharmaceutical
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 11
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims 5
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims 5
- 206010000496 acne Diseases 0.000 claims 5
- 229960003679 brimonidine Drugs 0.000 claims 5
- 229960001528 oxymetazoline Drugs 0.000 claims 5
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 208000010201 Exanthema Diseases 0.000 claims 3
- 206010043189 Telangiectasia Diseases 0.000 claims 3
- 201000005884 exanthem Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 206010037844 rash Diseases 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000009056 telangiectasis Diseases 0.000 claims 3
- 208000019872 Drug Eruptions Diseases 0.000 claims 2
- 206010015150 Erythema Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 231100000321 erythema Toxicity 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical group O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims 1
- 241001608562 Chalazion Species 0.000 claims 1
- 206010013786 Dry skin Diseases 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 206010015226 Erythema nodosum Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 208000009675 Perioral Dermatitis Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 241000220317 Rosa Species 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000009443 Vascular Malformations Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 229960001724 brimonidine tartrate Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000037336 dry skin Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 201000002597 ichthyosis vulgaris Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000008588 molluscum contagiosum Diseases 0.000 claims 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 claims 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical group Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000002453 shampoo Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 206010055031 vascular neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38726810P | 2010-09-28 | 2010-09-28 | |
| US61/387,268 | 2010-09-28 | ||
| US13/232,139 US20120076738A1 (en) | 2010-09-28 | 2011-09-14 | Combination treatment for dermatological conditions |
| US13/232,139 | 2011-09-14 | ||
| PCT/US2011/053455 WO2012050831A2 (en) | 2010-09-28 | 2011-09-27 | Combination treatment for dermatological conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013542930A JP2013542930A (ja) | 2013-11-28 |
| JP2013542930A5 true JP2013542930A5 (enExample) | 2014-09-18 |
Family
ID=45870879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013531721A Pending JP2013542930A (ja) | 2010-09-28 | 2011-09-27 | 皮膚科疾患の併用による治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20120076738A1 (enExample) |
| EP (1) | EP2621498A4 (enExample) |
| JP (1) | JP2013542930A (enExample) |
| KR (1) | KR20140056129A (enExample) |
| CN (1) | CN103354744A (enExample) |
| AU (1) | AU2011314151A1 (enExample) |
| CA (1) | CA2821993A1 (enExample) |
| MX (1) | MX2013003639A (enExample) |
| RU (1) | RU2013113188A (enExample) |
| WO (1) | WO2012050831A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130079312A1 (en) * | 2011-09-28 | 2013-03-28 | Elorac, Ltd. | Method of Treating Hair Loss Due to Systemic Chemotherapy |
| EP2994120B1 (en) * | 2013-05-06 | 2019-10-09 | Allergan, Inc. | Alpha adrenergic agonists for the treatment of tissue trauma |
| US20150258011A1 (en) * | 2014-03-15 | 2015-09-17 | Marty Richard Hunter | Treatment of keratinized tissues |
| US9597328B2 (en) * | 2015-02-24 | 2017-03-21 | Ocugen, Inc. | Methods and compositions for treating dry eye disease and other eye disorders |
| EP3319607A4 (en) * | 2015-07-09 | 2019-04-03 | Galderma S.A. | METHOD FOR REDUCING HAIR LOSS IN CONNECTION WITH CHEMOTHERAPY |
| RU2605687C1 (ru) * | 2015-09-21 | 2016-12-27 | Ирина Николаевна Усманова | Способ лечения рецидивирующего афтозного стоматита |
| CN110996904A (zh) | 2017-05-19 | 2020-04-10 | 奥古根有限公司 | 眼用组合物及使用方法 |
| US20190321416A1 (en) * | 2018-04-18 | 2019-10-24 | Forte Biosciences, Inc. | Compositions for the treatment of skin conditions |
| SG11202100985QA (en) * | 2018-08-29 | 2021-03-30 | Cellix Bio Private Ltd | Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases |
| WO2020065085A1 (fr) * | 2018-09-28 | 2020-04-02 | Galderma Research & Development | Composition pharmaceutique comprenant de la brimonidine, et ses utilisations |
| US20220096467A1 (en) * | 2019-01-12 | 2022-03-31 | Cellix Bio Provate Limited | Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof |
| KR20220002950A (ko) * | 2019-05-01 | 2022-01-07 | 클렉시오 바이오사이언시스 리미티드 | 소양증의 치료 방법 |
| WO2020222192A1 (en) * | 2019-05-01 | 2020-11-05 | Clexio Biosciences Ltd. | Methods of treating pruritus |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| US7812049B2 (en) * | 2004-01-22 | 2010-10-12 | Vicept Therapeutics, Inc. | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
| ES2424644T3 (es) * | 2004-05-25 | 2013-10-07 | Galderma Pharma S.A. | Compuestos, formulaciones y métodos para tratar o prevenir los trastornos inflamatorios de la piel |
| WO2009017705A1 (en) * | 2007-07-27 | 2009-02-05 | Galderma Laboratories L.P. | Compounds, formulations, and methods for reducing skin wrinkles, creasing and sagging |
| PT2818184T (pt) * | 2007-11-16 | 2019-01-28 | Aclaris Therapeutics Inc | Composições e métodos para o tratamento de púrpura |
| US8394800B2 (en) * | 2009-11-19 | 2013-03-12 | Galderma Laboratories, L.P. | Method for treating psoriasis |
| AU2011273509A1 (en) * | 2010-06-30 | 2013-06-13 | Galderma Research & Development | Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
| US20120082625A1 (en) * | 2010-09-28 | 2012-04-05 | Michael Graeber | Combination treatment for rosacea |
| WO2013057579A2 (en) * | 2011-10-19 | 2013-04-25 | Galderma Pharma S.A. | Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors |
-
2011
- 2011-09-14 US US13/232,139 patent/US20120076738A1/en not_active Abandoned
- 2011-09-27 EP EP11833012.5A patent/EP2621498A4/en not_active Withdrawn
- 2011-09-27 JP JP2013531721A patent/JP2013542930A/ja active Pending
- 2011-09-27 AU AU2011314151A patent/AU2011314151A1/en not_active Abandoned
- 2011-09-27 RU RU2013113188/15A patent/RU2013113188A/ru not_active Application Discontinuation
- 2011-09-27 CA CA2821993A patent/CA2821993A1/en not_active Abandoned
- 2011-09-27 KR KR1020137010903A patent/KR20140056129A/ko not_active Ceased
- 2011-09-27 WO PCT/US2011/053455 patent/WO2012050831A2/en not_active Ceased
- 2011-09-27 MX MX2013003639A patent/MX2013003639A/es unknown
- 2011-09-27 CN CN2011800470603A patent/CN103354744A/zh active Pending
-
2013
- 2013-12-10 US US14/101,464 patent/US20140094470A1/en not_active Abandoned
-
2015
- 2015-07-13 US US14/797,544 patent/US20150313895A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013113188A (ru) | Комбинированное лечение дерматологических состояний | |
| JP2013538853A5 (enExample) | ||
| JP2017537936A5 (enExample) | ||
| JP2013511534A5 (enExample) | ||
| BR112014009927A2 (pt) | "derivado de azol, composição farmacêutica que o compreende e uso do mesmo" | |
| CY1117183T1 (el) | Διακλαδισμενα παραγωγα 3-φαινυλοπροπιονικου οξεος και η χρηση τους | |
| EA201592250A1 (ru) | Пиразолопирролидиновые производные и их применение в лечение заболеваний | |
| CO6640250A2 (es) | Formulación tópica que comprende (r)-3-ciclopentil-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo o una sal farmaceúticamente aceptable del mismo y una emulsión de aceite en agua | |
| JP2013522184A5 (enExample) | ||
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| JP2014511393A5 (enExample) | ||
| NZ600333A (en) | Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis | |
| AR065317A1 (es) | Uso de quitosanos, derivados de quitosanos y una sal fisiologicamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales | |
| NZ594184A (en) | Skin treatment | |
| BR112015023669A2 (pt) | novos derivados de ciclosporina e suas utilizações | |
| MX2015013148A (es) | Nuevos compuestos de bencensulfonamida, metodo para sintetizar los mismos, y uso de los mismos en medicina asi como tambien en cosmeticos. | |
| JP2018522875A5 (enExample) | ||
| JP2020525460A5 (enExample) | ||
| WO2013022243A3 (ko) | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
| MY203497A (en) | Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments | |
| JP2010518139A5 (enExample) | ||
| BR112013007389A2 (pt) | derivado de 1,2,4-triazolona. | |
| MX2014014818A (es) | Composicion farmaceutica para el tratamiento de enfermedades inflamatorias de la piel. | |
| EA201590546A1 (ru) | Способы лечения заболеваний, связанных с волосами |